<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibodies</z:hpo> (<z:chebi fb="21" ids="53713">APAs</z:chebi>) are circulating immunoglobulins associated with a <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> combines <z:chebi fb="21" ids="53713">APAs</z:chebi> and clinical manifestations, including arterial or venous thromboses and/or recurrent spontaneous fetal loss </plain></SENT>
<SENT sid="2" pm="."><plain>The main risk incurred by endovascular treatment of <z:hpo ids='HP_0004944'>intracranial aneurysms</z:hpo> is the occurrence of <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We report two cases of patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> who developed thromboembolic complications after the endovascular treatment of unruptured <z:hpo ids='HP_0004944'>intracranial aneurysms</z:hpo> </plain></SENT>
</text></document>